熱門資訊> 正文

Essappslides在定价7500万美元股票发行后

2025-10-08 13:24

Esperion Therapeutics (NASDAQ:ESPR) priced an underwritten public offering of 30M shares at $2.50 each, aiming to raise about $75M in gross proceeds.
Underwriters have a 30-day option to buy up to 4.5M additional shares.
The offering is expected to close around October 9, 2025, subject to customary conditions.
ESPR --18.12% premarket to $2.53
Source: Press Release

More on Esperion Therapeutics

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now
Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs
Esperion rises after revenue beat, Q1 profitability expectation

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。